Our finding that ICG-001 effectively disrupts EGF- or SHCBP1-mediated CBP/β-catenin interaction and attenuates cellular stemness in NSCLC suggest that NSCLC patients with SHCBP1 upregulation might benefit from treatments of ICG-001. The gene discussed is SHCBP1; the disease is non-small cell lung carcinoma.